NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFIDAC 24 is an extended-release oral tablet formulation of chlorpheniramine maleate, a first-generation antihistamine used to treat allergic reactions and allergy symptoms. The drug works by blocking histamine H1 receptors, providing sustained symptomatic relief over an extended dosing interval.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals defensive positioning and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
Started Jan 2015
53 enrolled
Common Cold
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
Started Sep 2012
310 enrolled
Eczema
Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents
Started Dec 2008
36 enrolled
Allergic Reactions
Career Relevance
Working on EFIDAC 24 offers experience in defending a mature brand in a competitive generics environment and managing the commercial transition into LOE. Limited career growth potential given product lifecycle stage, but valuable exposure to cost-containment strategies, payer negotiations, and portfolio optimization.
Worked on EFIDAC 24 CHLORPHENIRAMINE MALEATE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.